openPR Logo
Press release

Retinitis Pigmentosa Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MeiraGTx, Aldeyra, SparingVision, ProQR Therapeutics, RetroSense, Endogena, Nacuity Pharmaceuticals, jCyte, Ocugen, Neurotech

02-23-2024 02:15 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Retinitis Pigmentosa Pipeline Assessment Covering Clinical

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Retinitis Pigmentosa therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Retinitis Pigmentosa Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Retinitis Pigmentosa Therapeutics Market.

The report provides a detailed description of the Retinitis Pigmentosa drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Retinitis Pigmentosa Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Retinitis Pigmentosa Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Retinitis Pigmentosa therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinitis Pigmentosa treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Retinitis Pigmentosa drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Retinitis Pigmentosa treatment market.

Learn More about the Clinical and Commercial Development Activities in the Retinitis Pigmentosa Therapeutics Domain @
https://www.delveinsight.com/report-store/retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Retinitis Pigmentosa Therapeutics Analysis
Around 40+ notable pharma and biotech companies are actively involved in the development of therapies for Retinitis pigmentosa. Among these, MeiraGTx stands out for having advanced Retinitis pigmentosa drug candidates in phase III clinical trials. Companies operating in the market collectively represent a diverse range of approaches and innovations aimed at addressing the challenges posed by Retinitis pigmentosa, a progressive eye disorder. Their dedication to advancing treatments offers hope for individuals affected by this condition and underscores the importance of ongoing research and development efforts in the field of ophthalmology.

Retinitis Pigmentosa Companies in the Therapeutics Market Include:
Some of the key companies in the Retinitis Pigmentosa Market include MeiraGTx, Aldeyra Therapeutics, Inc., SparingVision, Frontera Therapeutics, ProQR Therapeutics, BionicSight, RetroSense Therapeutics, Dompe Farmaceutici, Endogena Therapeutics, Nacuity Pharmaceuticals, Kiora Pharmaceuticals, jCyte, Ocugen, Neurotech USA, Nanoscope Therapeutics, and others.

Emerging and Marketed Retinitis Pigmentosa Therapies Covered in the Report Include:
• ADX-2191: Aldeyra Therapeutics, Inc.
• SPVN-06 : SparingVision
• FT-002: Frontera Therapeutics
• Botaretigene sparoparvovec: Johnson & Johnson Innovative Medicine /MeiraGTx
• MCO-010: Nanoscope Therapeutics
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Retinitis Pigmentosa Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Retinitis Pigmentosa Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Retinitis pigmentosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Retinitis Pigmentosa Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Retinitis Pigmentosa Current Treatment Patterns
4. Retinitis Pigmentosa - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Retinitis Pigmentosa Late-Stage Products (Phase-III)
7. Retinitis Pigmentosa Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Retinitis Pigmentosa Discontinued Products
13. Retinitis Pigmentosa Product Profiles
14. Retinitis Pigmentosa Companies
15. Retinitis Pigmentosa Drugs
16. Dormant and Discontinued Products
17. Retinitis Pigmentosa Unmet Needs
18. Retinitis Pigmentosa Future Perspectives
19. Retinitis Pigmentosa Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/retinitis-pigmentosa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Retinitis Pigmentosa Pipeline Assessment Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MeiraGTx, Aldeyra, SparingVision, ProQR Therapeutics, RetroSense, Endogena, Nacuity Pharmaceuticals, jCyte, Ocugen, Neurotech here

News-ID: 3397337 • Views:

More Releases from DelveInsight Business Research LLP

Postoperative Pain Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight
Postoperative Pain Market is Expected to Showcase a Significant Growth at a CAGR …
"The Postoperative Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Postoperative Pain pipeline products will significantly revolutionize the Postoperative Pain market dynamics" Key Takeaways from the Postoperative Pain Market Research Report • In 2022, the US captured the highest market share (85%), followed by Japan (7%), out of all the 7MM countries. • The Postoperative Pain market size in the
Amyotrophic Lateral Sclerosis Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight
Amyotrophic Lateral Sclerosis Market is Expected to Showcase a Significant Growt …
"The Amyotrophic Lateral Sclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Amyotrophic Lateral Sclerosis pipeline products will significantly revolutionize the Amyotrophic Lateral Sclerosis market dynamics" Key Takeaways from the Amyotrophic Lateral Sclerosis Market Research Report • The total Amyotrophic Lateral Sclerosis diagnosed prevalent cases in the 7MM and China were 59,130 and 29,095 in 2021, growing at a
Schizophrenia Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight
Schizophrenia Market is Expected to Showcase a Significant Growth at a CAGR of X …
"The Schizophrenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics" Key Takeaways from the Schizophrenia Market Research Report • In the year 2021, the total Schizophrenia prevalent cases were 6.27 million in the 7MM which are expected to grow during the study period, i.e., 2019-2032. • The highest number of total
Metachromatic Leukodystrophy Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)
Metachromatic Leukodystrophy Pipeline, FDA Approvals, Clinical Trials Developmen …
DelveInsight's, "Metachromatic Leukodystrophy Pipeline Insight 2024" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Metachromatic Leukodystrophy pipeline landscape. It covers the Metachromatic Leukodystrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metachromatic Leukodystrophy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Metachromatic Leukodystrophy

All 5 Releases


More Releases for Retinitis

Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Retinitis Pigmentosa (RP) Market Focusing on intrinsic limitations 2025
Global Retinitis Pigmentosa (RP) Market: Snapshot Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise. Request Sample Copy of
Retinitis Pigmentosa (Retinitis) Industry Market Expected To Grow At High Cagr D …
Overview Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.  Click here for sample report @ http://www.wiseguyreports.com/sample-request/2740087-retinitis-pigmentosa-retinitis-pipeline-review-h2-2017 Report Highlights The Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides comprehensive
Market Research Focuses on Retinitis Pigmentosa (Retinitis) Market Pipeline Revi …
"The Report Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape. Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision
Global Cytomegalovirus Retinitis Market Size, Share | MarketResearchReports.biz
Latest industry research report on: Global Cytomegalovirus Retinitis Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Cytomegalovirus (CMV) Retinitis is caused by cytomegalovirus infection, which is a herpes-type virus that affects the retina of the human eye among patients having a weak immune system that could be due to conditions such as AIDS, leukemia and/or pregnancy. Symptomatic conditions include floaters, flashes, and blind spots besides
Retinitis Pigmentosa (Retinitis) Pipeline Insight and Therapeutic Assessment Rev …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Retinitis Pigmentosa (Retinitis)-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Retinitis Pigmentosa (Retinitis). The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Retinitis Pigmentosa (Retinitis) by development stage, therapy